Frequency of triple mutations involving factor V, prothrombin, and methylenetetrahydrofolate reductase genes among patients referred for molecular thrombophilia workup in a tertiary care center in Lebanon

Genet Test Mol Biomarkers. 2012 Mar;16(3):223-5. doi: 10.1089/gtmb.2011.0114. Epub 2011 Oct 24.

Abstract

Aim: Molecular diagnostics has markedly improved the diagnosis and workup of different clinical conditions including hypercoagulable state or thrombophilia where different genes are involved. In this report, which is the largest report in the medical literature and the first in Lebanon, we describe the prevalence of simultaneous mutations in the three major thrombophilia genes Factor V, Factor II, and methylenetetrahydrofolate reductase.

Materials and methods: Using a polymerase chain reaction and reverse hybridization assay for the corresponding mutations identification, 2248 referred cases were analyzed.

Results: Only 25 cases were found to be simultaneously positive for the three mutations at a prevalence rate of 1.1%.

Conclusion: Compared with other populations, this prevalence rate is considered high, possibly the highest, and warrants future clinical studies and follow-up.

MeSH terms

  • Academic Medical Centers
  • Asian People / genetics*
  • Factor V / genetics*
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Humans
  • Lebanon / epidemiology
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Mutation*
  • Polymerase Chain Reaction
  • Prevalence
  • Prothrombin / genetics*
  • Referral and Consultation
  • Risk Factors
  • Thrombophilia / epidemiology
  • Thrombophilia / genetics*

Substances

  • Factor V
  • Prothrombin
  • MTHFR protein, human
  • Methylenetetrahydrofolate Reductase (NADPH2)